carvedilol has been researched along with Left Ventricular Hypertrophy in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We analyzed whether the use of a new beta adrenoceptor antagonist and vasodilator, carvedilol (CVD), slows the progression of nephrosclerosis and whether the renoprotective effect as well as reduction in cardiac hypertrophy is dependent on the degree of blood pressure reduction." | 7.69 | Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. ( Anabitarte, A; Cabrera, J; Llobet, J; Losada, A; Palop, L; Plaza, C; Rodriguez-Perez, JC, 1997) |
| "The hypothesis that left ventricular hypertrophy regression in hypertension relates to blood pressure (BP) control and to non-antihypertensive activity of some drugs was tested by comparing the effects of telmisartan and carvedilol on 24-h mean ambulatory BP and left ventricular mass (LVM) regression, measured using three-dimensional echocardiography (3-DECHO) and magnetic resonance imaging (MRI)." | 5.11 | Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. ( Breglio, R; Capogrosso, P; del Viscovo, L; Galzerano, A; Galzerano, D; Lama, D; Paolisso, G; Tammaro, P; Tuccillo, B, 2005) |
| "Carvedilol is a vasodilating, beta-adrenoceptor antagonist currently marketed for the treatment of mild to moderate hypertension." | 4.79 | Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. ( Feuerstein, GZ; Ruffolo, RR, 1995) |
| " We analyzed whether the use of a new beta adrenoceptor antagonist and vasodilator, carvedilol (CVD), slows the progression of nephrosclerosis and whether the renoprotective effect as well as reduction in cardiac hypertrophy is dependent on the degree of blood pressure reduction." | 3.69 | Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. ( Anabitarte, A; Cabrera, J; Llobet, J; Losada, A; Palop, L; Plaza, C; Rodriguez-Perez, JC, 1997) |
| "With carvedilol treatment, LVMI was lower (p<0." | 2.75 | Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. ( Mei, Z; Xiaozhen, H; Yu, S; Yun, Z, 2010) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Patients with hypertension are at increased risk of developing heart failure (HF), but the mechanisms by which hypertension leads to HF have not been clarified [although left ventricular hypertrophy (LVH) is clearly a predictor of an increased risk of HF]." | 2.40 | Progression from hypertension to heart failure. Mechanisms and management. ( Cleland, JG, 1999) |
| "Carvedilol treatment resulted in less left ventricular hypertrophy and dilatation." | 1.37 | Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation. ( Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A, 2011) |
| "Carvedilol at a lower dose (7." | 1.30 | Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. ( Donckier, J; Godfraind, T; Heyndrickx, GR; Kyselovic, J; Massart, PE; Wibo, M, 1999) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 6 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Degirmenci, H | 1 |
| Açikel, M | 1 |
| Bakirci, EM | 1 |
| Duman, H | 1 |
| Demirelli, S | 1 |
| Tas, H | 1 |
| Simsek, Z | 1 |
| Karakelleoglu, S | 1 |
| Aksakal, E | 1 |
| Erol, MK | 1 |
| Li, X | 1 |
| Matta, SM | 1 |
| Sullivan, RD | 1 |
| Bahouth, SW | 1 |
| Armenian, SH | 1 |
| Hudson, MM | 1 |
| Chen, MH | 1 |
| Colan, SD | 1 |
| Lindenfeld, L | 1 |
| Mills, G | 1 |
| Siyahian, A | 1 |
| Gelehrter, S | 1 |
| Dang, H | 1 |
| Hein, W | 1 |
| Green, DM | 1 |
| Robison, LL | 1 |
| Wong, FL | 1 |
| Douglas, PS | 1 |
| Bhatia, S | 1 |
| Jovanovic, D | 1 |
| Jovovic, D | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Miloradovic, Z | 1 |
| Naumovic, R | 1 |
| Dimitrijevic, J | 1 |
| Maksic, N | 1 |
| Djukanovic, L | 1 |
| Vitulano, N | 1 |
| Giubilato, G | 1 |
| Santangeli, P | 1 |
| Ierardi, C | 1 |
| Pieroni, M | 1 |
| Bellocci, F | 1 |
| Crea, F | 1 |
| Xiaozhen, H | 1 |
| Yun, Z | 1 |
| Mei, Z | 1 |
| Yu, S | 1 |
| Zendaoui, A | 1 |
| Lachance, D | 1 |
| Roussel, E | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Anguita Sánchez, M | 2 |
| Galzerano, D | 1 |
| Tammaro, P | 1 |
| del Viscovo, L | 1 |
| Lama, D | 1 |
| Galzerano, A | 1 |
| Breglio, R | 1 |
| Tuccillo, B | 1 |
| Paolisso, G | 1 |
| Capogrosso, P | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Bakris, GL | 1 |
| Tarka, EA | 1 |
| Waterhouse, B | 1 |
| Goulding, MR | 1 |
| Madan, A | 1 |
| Anderson, KM | 1 |
| St John Sutton, M | 1 |
| Miller, AB | 1 |
| Reichek, N | 1 |
| Hayduk, K | 1 |
| Feuerstein, GZ | 1 |
| Ruffolo, RR | 1 |
| Rodriguez-Perez, JC | 1 |
| Losada, A | 1 |
| Anabitarte, A | 1 |
| Cabrera, J | 1 |
| Llobet, J | 1 |
| Palop, L | 1 |
| Plaza, C | 1 |
| Massart, PE | 1 |
| Donckier, J | 1 |
| Kyselovic, J | 1 |
| Godfraind, T | 1 |
| Heyndrickx, GR | 1 |
| Wibo, M | 1 |
| Cleland, JG | 1 |
| Barth, W | 1 |
| Deten, A | 2 |
| Bauer, M | 1 |
| Reinohs, M | 1 |
| Leicht, M | 2 |
| Zimmer, HG | 2 |
| Sack, MN | 1 |
| Harrington, LS | 1 |
| Jonassen, AK | 1 |
| Mjøs, OD | 1 |
| Yellon, DM | 1 |
| Grimm, D | 1 |
| Huber, M | 1 |
| Jabusch, HC | 1 |
| Shakibaei, M | 1 |
| Fredersdorf, S | 1 |
| Paul, M | 2 |
| Riegger, GA | 1 |
| Kromer, EP | 1 |
| Briest, W | 1 |
| Hölzl, A | 1 |
| Rassler, B | 1 |
| Baba, HA | 1 |
| Pönicke, K | 1 |
| Heinroth-Hoffmann, I | 1 |
| Brodde, OE | 1 |
| Sarukhanian, OV | 1 |
| Torgomian, TG | 1 |
| Sisakian, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial[NCT02717507] | Phase 2 | 196 participants (Actual) | Interventional | 2016-04-04 | Active, not recruiting | ||
| A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Re[NCT00108082] | Phase 3 | 287 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of pills taken out of the total prescribed in a 3-month period, averaged across all study time points. The proportion of participants with average adherence rate >90% is computed by arm and corresponding 95% confidence intervals are reported. (NCT02717507)
Timeframe: Average adherence across 6 months, 12 months, 18 months, 24 months after treatment initiation are calculated.
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (Carvedilol) | 0.483 |
| Arm II (Placebo) | 0.517 |
Patients with toxicities reported via CTEP-AERS and all Grade ≥ 2 adverse events (AEs) that can be attributed probably or definitely to the study drug are considered to have AEs. The proportion of patients with AEs are reported by arm with corresponding 95% confidence intervals. (NCT02717507)
Timeframe: From baseline to month 24 since baseline
| Intervention | Proportion of patients with AE (Number) |
|---|---|
| Arm I (Carvedilol) | 0.0267 |
| Arm II (Placebo) | 0 |
"In a questionnaire, patients responded Yes/No to certain symptoms. If answered Yes, they selected slightly, moderately, quite a bit, or extremely regarding how bothersome the symptom was. The proportion of participants responding with any of these three categories was calculated by arm, and corresponding 95% confidence intervals are reported." (NCT02717507)
Timeframe: responses at days 14 to 730 were combined
| Intervention | Proportion of patients (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | Skin rash | Itchy skin | Dry Mouth | Easy bruising | Nosebleeds | Sunburn easily | Weight gain | Fluid retention | Swollen feet | Increased sweating | Feeling weak in parts of your body | Shortness of breath or wheezing | Chest pain or heaviness | Heart racing or skipping beats | Feeling shaky or having tremors | Decreased bodily movement | Feeling nervous | Feeling downhearted, sad, and/or tearful | Mood swings | Dizziness and/or lightheadedness | Dizziness upon standing (from sitting or lying down) | Insomnia | Difficulty concentrating | Interrupted sleep | Tendency to take naps | TiredwheezingFeeling unusually tired | Falling asleep at inappropriate times | Ringing in the ears | Difficulty breathing | Sensation that I have to urinate much of the time | Discoloration of urine (ie, bloody) | Decreased libido | Unusually heavy menstrual flows (N/A if postmenopausal or male) | |
| Arm I (Carvedilol) | 0.0533 | 0.0933 | 0.1467 | 0.0667 | 0.0133 | 0.0667 | 0.0933 | 0.0533 | 0.0267 | 0 | 0.0933 | 0.0933 | 0.0933 | 0.08 | 0.08 | 0.0533 | 0.0133 | 0.1467 | 0.2 | 0.12 | 0.16 | 0.1467 | 0.1733 | 0.1067 | 0.2 | 0.12 | 0.2267 | 0.0267 | 0.0533 | 0.0267 | 0.0667 | 0 | 0.0667 | 0.2 |
| Arm II (Placebo) | 0.1316 | 0.0789 | 0.1447 | 0.1711 | 0.0921 | 0.0526 | 0.0526 | 0.0789 | 0.0395 | 0.0921 | 0.0789 | 0.1316 | 0.0395 | 0.0921 | 0.0395 | 0.0789 | 0.0395 | 0.1711 | 0.1184 | 0.0921 | 0.1316 | 0.1579 | 0.1711 | 0.1316 | 0.2105 | 0.1053 | 0.2237 | 0.0395 | 0.0921 | 0 | 0.0789 | 0.0395 | 0.0526 | 0.111 |
A liver function measurement (in U/L). Normal range is 8-48 IU/L. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 29.122 | 28.014 | 30.148 | 27.196 | 29.86 |
| Arm II (Placebo) | 30.467 | 32.158 | 31.155 | 30.536 | 29.245 |
A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 26.608 | 24.068 | 25.426 | 24.375 | 24.561 |
| Arm II (Placebo) | 25.773 | 26.342 | 27.014 | 28.411 | 27.038 |
A liver function measurement (in mg/dL). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.5634 | 0.5973 | 0.563 | 0.593 | 0.5561 |
| Arm II (Placebo) | 0.4989 | 0.4942 | 0.4969 | 0.507 | 0.5449 |
N-terminal pro b-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 85.6301 | 90.7536 | 87.7167 | 99.4912 | 101.8333 |
| Arm II (Placebo) | 115.7222 | 128.9565 | 115.6364 | 93.2105 | 107.849 |
Troponin I is a biomarker for myocardial cell injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.00446 | 0.00265 | 0.00467 | 0.00737 | 0.01111 |
| Arm II (Placebo) | 0.0011 | 0.00174 | 0.00742 | 0.00684 | 0.01132 |
The percentage of blood leaving the heart at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | Percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 57.6 | 58.16 | 58.07 | 57.35 | 58.16 |
| Arm II (Placebo) | 57.42 | 56.84 | 56.61 | 57.6 | 57.5 |
A measure to assess preload and afterload (in %). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 28.5362 | 28.5409 | 29.6121 | 27.8219 | 28.0302 |
| Arm II (Placebo) | 28.4339 | 27.6866 | 28.1085 | 27.8891 | 28.5953 |
A protein produced by activated macrophages, and a member of a family of β-galactoside-binding lectings and promotes cardiac fibroblast proliferation and collagen synthesis following myocadial injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 4.4464 | 4.3252 | 3.7345 | 3.4548 | 3.8073 |
| Arm II (Placebo) | 5.2538 | 4.3735 | 4.3415 | 4.0214 | 4.0791 |
The amount of blood (in ml) in the heart's left ventricle just before the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 99.7507 | 99.3216 | 102.378 | 101.174 | 100.659 |
| Arm II (Placebo) | 93.3155 | 95.7434 | 96.5002 | 99.4656 | 98.9602 |
Thickness of cardiac muscle (in ml) of the left ventricle at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 4.5836 | 4.6035 | 4.636 | 4.6032 | 4.5147 |
| Arm II (Placebo) | 4.5269 | 4.565 | 0.0556 | 4.5462 | 4.5976 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | centimeter (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 03.2765 | 3.2901 | 3.262 | 3.32 | 3.2441 |
| Arm II (Placebo) | 3.2396 | 3.3023 | 3.2964 | 3.2798 | 3.286 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 42.2193 | 41.6128 | 42.8437 | 43.1453 | 42.0086 |
| Arm II (Placebo) | 39.7354 | 41.3839 | 41.8113 | 1.605 | 42.442 |
Echocardiographic measure of left ventricular (LV) afterload based on LV pressure (P), volume (V), and wall thickness (T), calculated by the formula (P x V)/T, which equals the number referred to below in the Measure Type. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/cm^2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 93.2892 | 90.3088 | 88.984 | 93.9267 | 89.2513 |
| Arm II (Placebo) | 90.6135 | 96.8356 | 96.0616 | 91.6458 | 94.0647 |
The weight of the left ventricle adjusted for body surface area (in g/m2). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/m2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 57.4862 | 58.2839 | 60.2116 | 57.7053 | 58.3315 |
| Arm II (Placebo) | 57.9322 | 57.0924 | 59.4508 | 59.1793 | 59.1026 |
Z-score of the ratio of left ventricular (LV) posterior wall dimension of systole to internal LV dimension in diastole, calculated for each subject by subtracting the reference healthy population mean, then dividing by the standard deviation. The Z-score indicates the number of standard deviations away from the mean of the reference population. Negative Z- score indicates worse outcome. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | z-score (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | -0.1372 | -0.2167 | -0.2416 | -0.2375 | 0.0213 |
| Arm II (Placebo) | -0.0893 | 0.3215 | -0.2367 | -0.1974 | 0.1834 |
B-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 27.3836 | 31.8406 | 26.8203 | 35.807 | 34.625 |
| Arm II (Placebo) | 31.4324 | 34.1857 | 33.2941 | 32.2807 | 33.3774 |
"Ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E wave) to peak velocity flow in late diastole caused by atrial contraction (A wave). Number shown for Unit of Measure refers to this ratio. Normal: >1. Impaired: <1. The mean is reported by arm at each timepoint with corresponding standard errors." (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ratio (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 1.728 | 1.642 | 1.723 | 1.732 | 1.603 |
| Arm II (Placebo) | 1.732 | 0.071 | 1.722 | 1.732 | 1.64 |
LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams (g) (Mean) |
|---|---|
| Carvedilol CR | -13.74 |
| Atenolol | -14.17 |
| Lisinopril | -17.17 |
LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams per meters squared (g/m^2) (Mean) |
|---|---|
| Carvedilol CR | -20.35 |
| Atenolol | -20.06 |
| Lisinopril | -18.48 |
LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams per meters squared (g/m^2) (Mean) |
|---|---|
| Carvedilol CR | -6.34 |
| Atenolol | -6.67 |
| Lisinopril | -7.94 |
LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)
| Intervention | g/m raised to 2.7 (g/(m^2.7)) (Mean) |
|---|---|
| Carvedilol CR | -11.78 |
| Atenolol | -12.51 |
| Lisinopril | -11.61 |
LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | g/m raised to 2.7 (g/(m^2.7)) (Mean) |
|---|---|
| Carvedilol CR | -3.19 |
| Atenolol | -3.37 |
| Lisinopril | -3.98 |
LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams (Mean) |
|---|---|
| Carvedilol CR | -45.76 |
| Atenolol | -40.56 |
| Lisinopril | -38.58 |
Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|---|
| Carvedilol CR | -27.1 |
| Atenolol | -20.1 |
| Lisinopril | -21.5 |
BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) [Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value]. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used
| Intervention | percentage of change (Geometric Mean) |
|---|---|
| Carvedilol CR | 51.7 |
| Atenolol | 48.3 |
| Lisinopril | -39.1 |
CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|---|
| Carvedilol CR | -10.63 |
| Atenolol | -3.22 |
| Lisinopril | 2.70 |
LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume). (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) | |
|---|---|---|
| LV E-volume | LV A-volume | |
| Atenolol | 6.763 | -0.565 |
| Carvedilol CR | 0.364 | -0.513 |
| Lisinopril | -3.406 | 1.088 |
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) | ||
|---|---|---|---|
| LV End Systolic Volume | LV End Diastolic Volume | LV Ejection Fraction | |
| Atenolol | -4.74 | -3.64 | 2.33 |
| Carvedilol CR | -3.38 | -3.07 | 1.03 |
| Lisinopril | -5.34 | -9.37 | 0.63 |
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) | ||
|---|---|---|---|
| LV End Systolic Volume | LV End Diastolic Volume | LV Ejection Fraction | |
| Atenolol | -4.29 | -2.45 | 2.16 |
| Carvedilol CR | -1.44 | -2.86 | 0.08 |
| Lisinopril | -3.04 | -7.45 | -0.01 |
Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | mmHg (millimeters of mercury) (Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Atenolol | -21.12 | -14.05 |
| Carvedilol CR | -21.32 | -12.77 |
| Lisinopril | -22.53 | -11.13 |
Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) | |||
|---|---|---|---|---|
| Total cholesterol | Low-density lipid cholesterol | High-density lipid cholesterol | Triglycerides | |
| Atenolol | -1.3 | -4.0 | -4.7 | 7.1 |
| Carvedilol CR | 0.7 | 0.0 | -4.3 | 11.0 |
| Lisinopril | -1.7 | -2.7 | -1.5 | 6.2 |
5 reviews available for carvedilol and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
How well are the cardiovascular risk profiles modulated by current beta blockers in hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiovascular Dis | 1993 |
Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Antioxidants; Arteriosclerosis; Carb | 1995 |
Progression from hypertension to heart failure. Mechanisms and management.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Humans; Hyp | 1999 |
3 trials available for carvedilol and Left Ventricular Hypertrophy
16 other studies available for carvedilol and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Carbazoles; C | 2014 |
Carvedilol reverses cardiac insufficiency in AKAP5 knockout mice by normalizing the activities of calcineurin and CaMKII.
Topics: A Kinase Anchor Proteins; Adrenergic Antagonists; Animals; Calcineurin; Calcium Signaling; Calcium-C | 2014 |
Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; Blood Pressu | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2013 |
Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Atrial Natri | 2011 |
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Delayed-Action Prepara | 2006 |
Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Hypertrophy, Left Vent | 1997 |
Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding.
Topics: Actins; Animals; Antihypertensive Agents; Aortic Diseases; Blood Pressure; Carbazoles; Carotid Arter | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen.
Topics: Adrenergic Antagonists; Animals; Atrial Natriuretic Factor; Calcium Channel Blockers; Carbazoles; Ca | 2000 |
Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats.
Topics: Acyl-CoA Dehydrogenase; Animals; Antihypertensive Agents; Carbazoles; Cardiomegaly; Carvedilol; Coen | 2000 |
Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agent | 2001 |
Cardiac remodeling after long term norepinephrine treatment in rats.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Blotting, Western; Calcium Channel Blockers; | 2001 |
Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Hypertrophy | 2002 |
Apoptosis in cardiac disease: from basics to clinics--an editorial commentary.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Animals; Apoptosis; Carbazoles; Carve | 2001 |
[A comparative study of anapriline and carvedilol effectiveness in patients with thyrotoxicosis in pre- and postoperative periods].
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Female; Humans; Hyperthyroidism; Hypertr | 2002 |